Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies

Cancer Chemotherapy and Pharmacology

Volumn 54, Issue 3, 2004, Pages 241-248

  Chow, Warren A ^a   Synold, Timothy W ^a   Tetef, Merry L ^a   Longmate, Jeffrey ^a   Frankel, Paul ^a   Lawrence, Joyce ^a   Al Khadimi, Zaid ^a   Leong, Lucille ^a   Lim, Dean ^a   Margolin, Kim ^a   Morgan Jr , Robert J ^a   Raschko, James ^a   Shibata, Stephen ^a   Somlo, George ^a   Twardowski, Przemyslaw ^a   Yen, Yun ^a   Doroshow, James H ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Anthracycline; Cardiotoxicity; Dexrazoxane; Doxorubicin; Pharmacokinetcs

Indexed keywords

ANTHRACYCLINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; LEVOFLOXACIN; RAZOXANE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADENOID CYSTIC CARCINOMA; ADULT; ANEMIA; ANOREXIA; ARTICLE; BLEEDING; BLOOD SAMPLING; BREAST CANCER; CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CARCINOSARCOMA; CAUSE OF DEATH; CLINICAL ARTICLE; CLINICAL TRIAL; DEHYDRATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INFUSION; DRUG MEGADOSE; DYSPHAGIA; DYSPNEA; EPITHELIOID SARCOMA; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FIBROSARCOMA; GRANULOCYTE; HALLUCINATION; HEART EJECTION FRACTION; HEART INJURY; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; HYPOXIA; INFECTION; LEUKOCYTE; LEUKOCYTE COUNT; LIPOSARCOMA; MALE; NAUSEA; NEUROFIBROSARCOMA; NEUTROPHIL; OVARY CANCER; PLASMA; PRIORITY JOURNAL; PROTHROMBIN TIME; RHABDOMYOSARCOMA; SEPSIS; SIDE EFFECT; SOFT TISSUE; STOMATITIS; SYNCOPE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THYMOMA; TYPHLITIS;

EID: 4344658764     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0803-4     Document Type: Article

References (41)

1. Bakowski MT, Prentice HG, Lister TA, Malpas JS, McElwain TJ, Powles RL (1979) Limited activity of ICRF-159 in advanced acute leukemia. Cancer Treat Rep 63:127
2. Bellet RE, Engstrom PF, Catalano RB, Creech RH, Mastrangelo MJ (1976) Phase II study of ICRF-159 in patients with metastatic colorectal carcinoma previously exposed to systemic chemotherapy. Cancer Treat Rep 60:1935
3. Billingham ME, Bristow MR, Glatstein E, Mason JW, Masek MA, Daniels JR (1975) Adriamycin cardiotoxicity: endomyocardial biopsy evidence of enhancement by irradiation. Am J Surg Pathol 1:17
4. Bristow MR, Thompson PD, Martin RP, Mason JW, Billingham ME, Harrison DC (1978) Early anthracycline cardiotoxicity. Am J Med 65:823
5. Bugat R, Robert J, Herrera A, Pinel MC, Huet S, Chevreau C, Boussin G, Roquain J, Carton M (1989) Clinical and pharmacokinetic study of 96-h infusions of doxorubicin in advanced cancer patients. Eur J Cancer Clin Oncol 25:505
6. Casper ES, Gaynor JJ, Hajdu SI, Magill GB, Tan C, Freidrich C, Brennan MF (1991) A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors. Cancer 68:1221
7. Doroshow JH (1995) Role of reactive-oxygen metabolism in the cardiac toxicity of the anthracycline antibiotics. In: Priebe W (ed) Anthracycline antibiotics: new analogues, methods of delivery, and mechanisms of action. American Chemical Society, Washington, p 259
8. Eagan RT, Carr DT, Coles DT, Rubin J, Frytak S (1976) ICRF-159 versus polychemotherapy in non-small cell lung cancer. Cancer Treat Rep 60:947
9. Ellis MJ, Hayes DF, Lippman ME (2000) Treatment of metastatic breast cancer. In: Harris JR, Lippman ME, Morrow M (eds) Diseases of the breast (2nd edn). Lippincott Williams & Wilkins, Philadelphia, p 749
10. Fisher B, Redmond C, Wickerham KL, Bowman D, Schipper H, Wolmark N, Sass R, Fischer ER, Jochimsen P, Legault-Poisson S (1989) Doxorubicin-containing regimens for the treatment of stage II breast cancer: the National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol 7:572
11. Fisher B, Redmonds C, Legault-Poisson S, Dimitrov NV, Brown AM, Wickerham KL, Wolmark N, Margolese RG, Bowman D, Glass AG (1990) Post-operative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 8:1005
12. Flannery EP, Corder MP, Shehan WW, Pajak TF, Bateman JR (1978) Phase II study of ICRF-159 in non-Hodgkin's lymphomas. Cancer Treat Rep 62:465
13. Hasinoff BB (1990) The iron(III) and copper(II) complexes of adriamycin promote the hydrolysis of the cardioprotective agent ICRF-187 ((+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane). Agents Actions 29:374
14. Herman EH, Mhatre RM, Lee IP, Waravdekar VS (1972) Prevention of the cardiotoxic effects of adriamycin and daunomycin in the isolated dog heart. Proc Soc Exp Biol Med 140:234
15. Herman EH, Mhatre RM, Chadwick DP (1974) Modification of some of the toxic effects of daunomycin (NSC-82, 151) by treatment with the antineoplastic agent ICRF-159 (NSC-129,943). Toxicol Appl Pharmacol 27:517
16. Herman EH, Ferrans VJ, Jordan W, Ardalan B (1981) Reduction of chronic daunorubicin cardiotoxicity by ICRF-187 in rabbits. Res Commun Chem Pathol Pharmacol 31:85
17. Hitchcock-Bryan S, Gelber R, Cassady JR, Sallan SE (1986) The impact of induction anthracycline on long-term failure-free survival in childhood acute lymphoblastic leukemia. Med Pediatr Oncol 14:211
18. Hochster H, Liebes L, Wadler S, Oratz R, Wernz JC, Meyers M, Green M, Blum RH, Speyer JL (1992) Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. J Natl Cancer Inst 84:1725
19. Kremer LCM, van Dalen EC, Offringa M, Ottenkamp J, Voûte PA (2001) Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol 19:191
20. Legha SS, Benjamin RS, Mackay B, Ewer M, Wallace S, Valdivieso M, Rasmussen SL, Blumenschein GR, Freireich EJ (1982) Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 96:133
21. Liesmann J, Belt R, Haas C, Hoogstraten B (1981) Phase I evaluation of ICRF-187 (NSC-169780) in patients with advanced malignancy. Cancer 47:1959
22. Marciniak TA, Moertel CG, Schutt AJ, Hahn RG, Reitemeir RJ (1975) Phase II study of ICRF-159 (NSC-129943) in advanced colorectal carcinoma. Cancer Chemother Rep 59:761
23. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207
24. Minow RA, Benjamin RS, Gottlieb JA (1975) Adriamycin (NSC-123127) cardiomyopathy - an overview with determination of risk factors. Part 3. Cancer Chemother Rep 6:195
25. Morgan RJ Jr, Doroshow JH, Venkataraman K, Chang K, Raschko J, Somlo G, Leong L, Tetef M, Shibata S, Hamasaki V, Margolin K, Forman S, Akman S, Coluzzi P, Ahn C, Weiss L, Gadgil U, Harrison J (1997) High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support. Clin Cancer Res 3:2337
26. Olweny CL, Masaba JP, Sikyewunda W, Toya T (1976) Treatment of Kaposi's sarcoma with ICRF-159 (NSC 129943). Cancer Treat Rep 60:111
27. Shah MK, Engstrom PF, Catalano RB, Paul AR, Bellet RE, Creech RH (1979) Phase II trial of ICRF-159 in previously treated patients with head and neck carcinoma (abstract). Proc Am Soc Clin Res 20:366a
28. Smith MA, Ungerleider RS, Horowitz ME, Simon R (1991) Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. J Natl Cancer Inst 83:1460
29. Somlo G, Doroshow JH, Forman SJ, Leong LA, Margolin KA, Morgan RJ Jr, Raschko JW, Akman SA, Ahn C, Schmidt GM, Brent J, Rincon A, Nagasawa S (1994) High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. Cancer 73:1678
30. Speyer JL, Green MD, Kramer E, Rey M, Sanger J, Ward C, Dubin N, Ferrans V, Stecy P, Zeleniuch-Jacquotte A, Wernz J, Feit F, Meyers M, Slater W, Taubes S, Blum R, Muggia F (1988) Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 319:745
31. Speyer JL, Green MD, Zeleniuch-Jacquotte A, Wernz JC, Rey M, Sanger J, Kramer E, Ferrans V, Hochster H, Meyers M, Blum RH, Feit F, Attubato M, Burrows W, Muggia FM (1992) ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 10:117
32. Swain SM, Whaley FS, Gerber MC, Ewer MS, Bianchine JR, Gams RA (1997) Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol 15:1333
33. Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D, Jones SE, Wadler S, Desai A, Vogel C, Speyer J, Mittelman A, Reddy S, Pendergrass K, Velez-Garcia E, Ewer MS, Bianchine JR, Gams RA (1997) Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 15:1318
34. Swain SM, Whaley FS, Ewer MS (2003) Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97:2869
35. Synold TW, Doroshow JH (1996) Anthracycline dose intensity: clinical pharmacology and pharmacokinetics of high-dose doxorubicin administered as a 96-hour continuous intravenous infusion. J Infusional Chemother 6:69
36. Synold TW, Spencer M, Doroshow JH (1997) Dexrazoxane potentiates the cytotoxic activity of topotecan in a sequence and schedule dependent manner (abstract). Proc Am Assoc Cancer Res 38:2161a
37. Tetef ML, Synold TW, Chow W, Leong L, Margolin K, Morgan R, Raschko J, Shibata S, Somlo G, Yen Y, Groshen S, Johnson K, Lenz H-J, Gandara D, Doroshow JH (2001) Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies. Clin Cancer Res 7:1569
38. Von Hoff DD, Layard MW, Bassa P, Davis HL Jr, Von Hoff AL, Rozencweig M, Muggia FM (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710
39. Von Hoff DD, Howser D, Lewis BJ, Holcenberg J, Weiss RB, Young RC (1981) Phase I study of ICRF-187 using a daily for 3 days schedule. Cancer Treat Rep 65:249
40. Wadler S, Green MD, Basch R, Muggia F (1987) Lethal and sublethal effects of the combination of doxorubicin and the bisdioxopiperazine, (+)-1,2,-bis(3-5-dioxopiperazinyl-1-yl) propane (ICRF 187), on murine sarcoma S180 in vitro. Biochem Pharmacol 36:1495
41. Woods WC, Budman DR, Korzun AH, Cooper MR, Younger J, Hart RD, Moore A, Ellerton JA, Norton L, Ferree CL, Colangelo-Bellow A, Frei M, Henderson IC (1994) Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 330:1253